BASTA JAMES
SEC insider (Form 3/4/5 filer). CIK 0001792726. EVP, General Counsel at Intellia Therapeutics, Inc. (NTLA). 6 reported Form 4/5 transactions since Sep 2024; latest on Mar 2, 2026. Located in CAMBRIDGE, MA.
Companies BASTA JAMES has filed insider reports for
- Intellia Therapeutics, Inc. (NTLA): Officer, EVP, General Counsel
BASTA JAMES
CIK: 0001792726
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Intellia Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Mar 2, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect1.2K shares at avg. $13.78$17K - Mar 1, 2026NTLA
Intellia Therapeutics, Inc.
AwardDirect46.1K shares- - Jan 5, 2026NTLA
Intellia Therapeutics, Inc.
SaleDirect10.4K shares at avg. $9.21$96K - Mar 4, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect2.6K shares at avg. $8.99$23K - Mar 1, 2025NTLA
Intellia Therapeutics, Inc.
AwardDirect40K shares- - Jan 3, 2025NTLA
Intellia Therapeutics, Inc.
SaleDirect7.1K shares at avg. $12.18$86K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 2, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 1,211 | $13.78 | $16,688 | Direct |
| Mar 1, 2026 | NTLA Intellia Therapeutics, Inc. | Award | 46,080 | - | $0 | Direct |
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Sale | 10,397 | $9.21 | $95,756 | Direct |
| Mar 4, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 2,572 | $8.99 | $23,122 | Direct |
| Mar 1, 2025 | NTLA Intellia Therapeutics, Inc. | Award | 40,000 | - | - | Direct |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | Sale | 7,074 | $12.18 | $86,161 | Direct |
1-6 of 6 transactions